Journal Article DZNE-2026-00606

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2026
Elsevier Masson SAS [Paris]

The journal of prevention of Alzheimer's disease 13(8), 100609 () [10.1016/j.tjpad.2026.100609]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Subjective cognitive decline is common in older adults and may represent an early clinical signal along the Alzheimer's disease continuum. The clinical relevance of longitudinal changes in subjective cognitive decline remains unclear.To determine whether trajectories of self- or study partner-reported cognitive decline predict progression to mild cognitive impairment and reflect Alzheimer's disease-specific biological patterns.Data were pooled from two observational cohorts. Cognitively unimpaired participants with baseline amyloid status, repeated assessments of subjective cognitive decline, and clinical follow-up were included. The study included 770 participants with a median follow-up of 5.0 years (interquartile range 4.0-7.0).Subjective cognitive decline was assessed using the Everyday Cognition questionnaire completed by participants and study partners. Linear mixed-effects models examined associations with amyloid status and progression to mild cognitive impairment. Cox proportional hazards models tested whether one-year changes predicted progression.Amyloid-positive participants and those who progressed to mild cognitive impairment showed steeper increases in self- and study partner-reported cognitive difficulties over time. Among amyloid-positive participants, only increases in study partner-report differentiated progressors from non-progressors. One-year increases in study partner-report predicted a higher risk of mild cognitive impairment compared with unchanged scores (hazard ratio 3.24; 95% confidence interval 1.73-6.07]), with effects confined to amyloid-positive participants.Short-term increases in study partner-reported cognitive difficulties identify amyloid-positive cognitively unimpaired older adults at increased risk of near-term progression to mild cognitive impairment. Longitudinal monitoring using study partner reports may provide a low-burden and clinically relevant approach for early risk stratification and surveillance in aging populations.

Keyword(s): Alzheimer’s pathology ; Clinical progression ; Self-report ; Study partner report ; Subjective cognitive decline

Classification:

Contributing Institute(s):
  1. Neuropsychology (AG Wagner)
  2. Biomarker-Assisted Early Detection of Dementias (AG Peters)
  3. Interdisciplinary Dementia Research (AG Endres)
  4. Translational Neuropsychiatry (AG Priller)
  5. Translational Dementia Research (Bonn) (AG Schneider)
  6. Patient Studies (Bonn) (Patient Studies (Bonn))
  7. Molecular biomarkers for predictive diagnostics of neurodegenerative diseases (AG Wiltfang)
  8. Clinical Neurophysiology and Memory (AG Düzel)
  9. Molecular Neurobiology (AG Simons)
  10. Vascular Cognitive Impairment & Post-Stroke Dementia (AG Dichgans)
  11. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)
  12. Parkinson Genetics (AG Gasser)
  13. Core ICRU (ICRU)
  14. Clinical Research Platform (CRP) (AG Spottke)
  15. Neuroinflammation, Biomarker (AG Heneka)
  16. Clinical Alzheimer’s Disease Research (AG Jessen)
  17. Mathematics, statistics and informatics methods for support of population studies and clinical research (AG Schmid Bonn)
  18. Clinical Research (Munich) (Clinical Research (Munich))
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
  2. 351 - Brain Function (POF4-351) (POF4-351)
Experiment(s):
  1. Longitudinal Cognitive Impairment and Dementia Study

Database coverage:
Medline ; DOAJ ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Springer ; DEAL Springer ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > M DZNE > M DZNE-Clinical Research (Munich)
Institute Collections > BN DZNE > BN DZNE-Patient Studies (Bonn)
Document types > Articles > Journal Article
Institute Collections > GÖ DZNE > GÖ DZNE-AG Wiltfang
Institute Collections > BN DZNE > BN DZNE-AG Schneider
Institute Collections > ROS DZNE > ROS DZNE-AG Teipel
Institute Collections > TÜ DZNE > TÜ DZNE-AG Gasser
Institute Collections > BN DZNE > BN DZNE-AG Spottke
Institute Collections > BN DZNE > BN DZNE-AG Jessen
Institute Collections > MD DZNE > MD DZNE-AG Düzel
Institute Collections > BN DZNE > BN DZNE-AG Wagner
Institute Collections > BN DZNE > BN DZNE-AG Heneka
Institute Collections > M DZNE > M DZNE-AG Dichgans
Institute Collections > B DZNE > B DZNE-AG Priller
Institute Collections > M DZNE > M DZNE-AG Simons
Institute Collections > B DZNE > B DZNE-AG Peters
Institute Collections > B DZNE > B DZNE-AG Endres
Institute Collections > TÜ DZNE > TÜ DZNE-ICRU
Documents in Process
BN DZNE-AG Schmid Bonn
Public records
In process

 Record created 2026-06-11, last modified 2026-06-11


Restricted:
Download fulltext PDF Download fulltext PDF (PDFA)
External link:
Download fulltextFulltext by Pubmed Central
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)